Psyence Biomedical
PBM · NASDAQ · Health Care · Pharmaceutical Preparations
Pharmaceutical Preparations company based in Toronto. Foreign private issuer: reports on Form 20-F or 40-F. Its directors and officers file insider-trading forms (Form 4) only since 18 March 2026.
As of Oct 20, 2026, OQRO holds for Psyence Biomedical (PBM) over the last 12 months: 0 insider filings, 0 Congress trades, 2 fund positions and 0 federal contract awards.
Last 30 days
Written by software from the filings listed below · Oct 19, 2026
- Funds and stakes. Psyence Labs Ltd. disclosed a 49.8% stake in PBM (filed Oct 15, 2026). AdvisorShares Trust now owns 6.8% of PBM as a passive investor (filed Oct 5, 2026). (Psyence Biomedical on OQRO)
- Contracts, lobbying and filings. FINRA short interest for PBM on the settlement date of Sep 30, 2026 was 26,839 shares (-44.34% on the previous report), about 1 days of average volume.
- Company reports, price and press. Press coverage listed by Finnhub: "Psyence BioMed Partners with DEA-Registered Benuvia Operations to Establish U.S. Manufacture of Pharmaceutical-Grade Ibogaine" (Yahoo, Oct 5, 2026). Press coverage listed by Finnhub: "Psyence BioMed Announces Exclusive U.S. Ibogaine Licence for Texas Ibogaine Research Corporation" (Yahoo, Sep 28, 2026).
- Things to keep in mind. These are counts of the filings OQRO holds, in the days they were filed; a busy or quiet month does not say why. A Form 4 reports a transaction; it does not say why it was made, and some follow trading windows or pre-arranged plans. Congress reports give only amount ranges and arrive after the trade. Headlines are listed as published by the outlets; OQRO has not checked them and does not summarise articles.
Facts used for this text
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Funds and stakes
- Psyence Labs Ltd. disclosed a 49.8% stake in PBM (filed Oct 15, 2026).
- AdvisorShares Trust now owns 6.8% of PBM as a passive investor (filed Oct 5, 2026).
Contracts, lobbying and filings
- FINRA short interest for PBM on the settlement date of Sep 30, 2026 was 26,839 shares (-44.34% on the previous report), about 1 days of average volume.
Company reports, price and press
- Press coverage listed by Finnhub: "Psyence BioMed Partners with DEA-Registered Benuvia Operations to Establish U.S. Manufacture of Pharmaceutical-Grade Ibogaine" (Yahoo, Oct 5, 2026).
- Press coverage listed by Finnhub: "Psyence BioMed Announces Exclusive U.S. Ibogaine Licence for Texas Ibogaine Research Corporation" (Yahoo, Sep 28, 2026).
- Press coverage listed by Finnhub: "Psyence BioMed Announces Strategic Ibogaine Investment" (Yahoo, Sep 23, 2026).
- PBM closed at $4.22 on Oct 16, 2026, the last session on or before the end of the period.
- From Sep 16, 2026 to Oct 16, 2026, the close moved from $5.82 to $4.22, a change of −27.5%.
Things to keep in mind
- These are counts of the filings OQRO holds, in the days they were filed; a busy or quiet month does not say why.
- A Form 4 reports a transaction; it does not say why it was made, and some follow trading windows or pre-arranged plans. Congress reports give only amount ranges and arrive after the trade.
- Headlines are listed as published by the outlets; OQRO has not checked them and does not summarise articles.
- Share price moves are listed as context only; the filing does not explain them and other news can move a price.
- This describes public filings. It is not investment advice.
Example public filing
No filing stored for Psyence Biomedical in the last 12 months.
Nothing from insiders, Congress, funds or federal contracts dated in this period. See a real example on the home page, which shows live filings free.
On file for PBM, last 12 months
- 0
- Insider filings
- 0
- Congress trades
- 2
- Fund positions
- 0
- Federal contracts
Records OQRO holds, counted by their date; a 13F position is counted once per quarter it is reported.
See the full picture with OQRO Pro.
2 records for Psyence Biomedical in the last 12 months, each linked to its filing. Full histories, the screener, alerts for the companies you follow and Ask OQRO.
Latest disclosures
3 days free for first-time subscribers, then $9.99 a month. Nothing is charged today: your card is charged when the trial ends unless you cancel before, from your account. Secure payment by Stripe.
Public previews are free. Full research is OQRO Pro, with a 3-day free trial to start: your card is charged only when the trial ends.
Free account: get the written context of this page, built from its filings.
What this page holds
- Insider trades and planned sales
- Politician trades (House and Senate)
- Fund holdings from 13F filings
- Federal contracts, lobbying and short selling
- Full history and context, with a link to every filing
What OQRO is
OQRO reads the public record for US-listed companies — insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings, and federal contract awards — and puts each one in plain words next to the filing it came from. It describes what was disclosed. It does not give investment advice or tell you what to buy.
Want to see real filings before you pay? The home page shows live ones, free, with the link to each source document.
Questions about Psyence Biomedical insider trading
Have Psyence Biomedical insiders bought shares recently?
No open-market purchase by an insider of Psyence Biomedical is on record in SEC filings since 2006.
Do members of Congress trade PBM?
No trade in Psyence Biomedical (PBM) was disclosed by a member of Congress in the last 12 months.
Where does this data come from?
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.